ArticleCadernos de saude publica2026
[Expansion of the use of technologies to reduce cases of malaria due to Plasmodium vivax in the Brazilian Amazon: a budget impact analysis].
Article in Cadernos de saude publica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tafenoquine and primaquine are drugs used in the treatment of malaria due to Plasmodium vivax, but can cause hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) enzyme deficiency. Thus, G6PD testing is recommended prior to drug administration. Tafenoquine and the G6PD quantitative point-of-care test are incorporated into the Brazilian Unified National Health System (SUS) for individuals over 16 years of age, but are not available for younger patients or by weight range. Testing for all patients eligible for primaquine treatment is also not offered in the SUS. The aim of the present study was to calculate the incremental budgetary impact of the incorporation of tafenoquine and testing for G6PD deficiency in individuals under 16 years of age and by weight. The expansion of testing for patients eligible for treatment with primaquine was also considered. The perspective of the analysis is that of the SUS for a five-year horizon. The reference population was that of the Brazilian Amazon. A budget impact model was developed and validated by managers and specialists in malaria and pharmaceutical services in the SUS. The incremental budget impact was BRL 12.5 million. The model predicted that incorporating tafenoquine would reduce hospitalization and recurrence costs by about 9% and 11%, respectively. The cost and waste of the test reagent strips impacted the results. The technologies analyzed can contribute to safer decision-making in the treatment of malaria in the Brazilian Amazon and planning if the technologies under analysis are incorporated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.